Surgical prevention of cancer

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 324-332

  Bertagnolli, Monica M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; ENDOMETRIUM CANCER; ENTERITIS; ESOPHAGUS CANCER; HUMAN; MORBIDITY; OVARY CANCER; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SURGICAL TECHNIQUE; THYROID CANCER; DECISION MAKING; FAMILIAL CANCER; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; RISK ASSESSMENT; RISK FACTOR;

DECISION MAKING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; RISK ASSESSMENT; RISK FACTORS;

EID: 13744255220     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.096     Document Type: Review

References (61)

1. Sudbo J, Lippman SM, Lee JJ, et al: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350:1405-1413, 2004
2. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 22:1055-1062, 2004
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
4. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271, 1995
5. Li FP, Fraumeni JF, Jr.: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752, 1969
6. Nelen MR, Padberg GW, Peeters EA, et al: Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13:114-116, 1996
7. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
8. Hartmann LC, Schaid DJ, Woods JE: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
9. Eng C: Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet 37:828-830, 2000
10. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
11. Birch JM, Blair V, Kelsey AM, et al: Cancer phenotype correlates with constitutional TP53 genotype families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068, 1998
12. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
13. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
14. Lee JS, Grant CS, Donohue JH, et al: Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118:640-648, 1995
15. Tavassoli FA: Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 11:140-154, 1998
16. Leonard GD, Swain SM: Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96:906-920, 2004
17. Burstein HJ, Polyak K, Wong JS, et al: Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441, 2004
18. Silverstein MJ, Lagios MD, Groshen S, et al: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455-1461, 1999
19. Bijker N, Peterse JL, Duchateau L, et al: Histological type and marker expression of the primary tumour compared with its local recurrence after breast-concerving therapy for ductal carcinoma in situ. Br J Cancer 84:539-544, 2001
20. Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998
21. Allred DC, Bryant J, Land S, et al: Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat 76:S36, 2002 (abstr 30)
22. Satagopan JM, Boyd J, Kauft ND, et al: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8:3776-3781, 2002
23. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
24. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 73:1117-1130, 2003
25. Vasen HF, Wijnen JT, Menko FA, et al: Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020-1027, 1996
26. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273:491-497, 1995
27. Winawer SJ, Zauber AG, Ho MN, et al: Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329:1977-1981, 1993
28. Kinzler KW, Nilbert MC, Su L-K, et al: Identification of FAP locus genes from chromosome 5q21. Science 253:661-665, 1991
29. Groden J, Thliveris A, Samowitz W, et al: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589-600, 1991
30. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
31. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
32. Nugent KP, Phillips RK: Rectal cancer risk in older patients with familial adenomatous polyposis. Br J Surg 79:1204-1206, 1992
33. Penna D, Karthueser A, Parc R, et al: Secondary proctectomy and ileal pouch-anal anastomosis after ileorectal anastomosis for familial adenomatous polyposis. Br J Surg 80:1621-1623, 1993
34. Heiskanen I, Jarvinen H: Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis 12:9-13, 1997
35. Parc YR, Moslein G, Dozois RR, et al: Familial adenomatous polyposis: Results after ileal pouch-anal anastomosis in teenagers. Dis Colon Rectum 43:893-898, 2000
36. Lynch HG, Smyrk T: Hereditary nonpolyposis colorectal cancer (Lynch syndrome): An updated review. Cancer 78:1149-1167, 1996
37. Rodriguez-Bigas MA: Prophylactic colectomy for gene carriers in hereditary nonpolyposis colorectal cancer: Has the time come? Cancer 78:199-201, 1996
38. Lennard-Jones JE, Melville DM, Morson BC, et al: and C.B., W. Precancer and cancer in extensive ulcerative colitis: Findings among 401 patients over 22 years. Gut 31:800-806, 1990
39. Friedman S, Rubin PH, Bodian C, et al: Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 120:820-826, 2001
40. Rutter M, Saunders B, Wilkinson K, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451-459, 2004
41. Itzkowitz SH, Yio X: Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7-G17, 2004
42. Lashner BA: Recommendations for colorectal cancer screening in ulcerative colitis: A review from a single university-based surveillance program. Am J Gastroenterol 87:168-175, 1992
43. Morpurgo E, Petras R, Kimberling J, et al: Characterization and clinical behavior of Crohn's disease initial presenting predominantly as colitis. Dis Colon Rectum 46:918-924, 2003
44. Watson P, Vansen HFA, Mecklin JP, et al: The risk of entometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96:516-519, 1994
45. Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915-919, 1997
46. Guilford P, Hopkins J, Harraway J, et al: E-cadherin germline mutations in familial gastric cancer. Nature 392:402-405, 1998
47. Huntsman DG, Carneiro F, Lewis FR, et al: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904-1909, 2001
48. Ruol A, Zaninotto G, Costantini M, et al: Barrett's esophagus: Management of high-grade dysplasia and cancer. J Surg Res 117:44-51, 2004
49. Headrick JR, Nichols FC, Miller DL, et al: High-grade esophageal dysplasia: Long-term survival and quality of life after esophagectomy. Ann Thorac Surg 73:1697-1702, 2002
50. Sampliner RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97:1888-1895, 2002
51. Tseng EE, Wu TT, Yeo CJ, et al: Barrett's esophagus with high grade dysplasia: Surgical results and long-term outcome-an update. J Gastrointest Surg 7:164-170, 2003
52. Begg CB, Cramer LDS, Hoskins WJ, et al: Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747-1751, 1998
53. Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002
54. Frilling A, Weber F, Tecklenborg C, et al: Prophylactic thyroidectomy in multiple endocrine neoplasia: The impact of molecular mechanisms of RET proto-oncogene. Langenbecks Arch Surg 388:17-26, 2003
55. Wells SA Jr, Chi DD, Toshima K, et al: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-250, 1994
56. Wells SA Jr, Skinner MA: Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 106:29-34, 1998
57. Lynch HT, Smyrk T, Kern SE, et al: Familial pancreatic cancer: A review. Semin Oncol 23:251-275, 1996
58. Bartsch DK: Familial pancreatic cancer. Br J Surg 90:386-387, 2003
59. Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: An increasingly recognized clinicopathologic entity. Ann Surg 234:313-322, 2001
60. Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: An updated experience. Ann Surg 239:788-799, 2004
61. Salvia R, Fernandez-del Castillo C, Bassi C, et al: Main-duct intraductal papillary mucinous neoplasms of the pancreas: Clinical predictors of malignancy and long-term survival following resection. Ann Surg 239:678-687, 2004